scholarly journals Scientific Opinion on the substantiation of a health claim related to a combination of Lactobacillus helveticus CNCM I-1722, Bifidobacterium longum subsp. infantis CNCM I-3424, Bifidobacterium bifidum CNCM I 3426 and fructo oligosaccharides from sucrose a

EFSA Journal ◽  
2012 ◽  
Vol 10 (8) ◽  
pp. 2852 ◽  
Author(s):  
Keyword(s):  
Bifidobacterium Longum ◽  
Bifidobacterium Bifidum ◽  
Lactobacillus Helveticus ◽  
Health Claim ◽  
Scientific Opinion

scholarly journals Bifidobacterium bifidum R0071 results in a greater proportion of healthy days and a lower percentage of academically stressed students reporting a day of cold/flu: a randomised, double-blind, placebo-controlled study

2015 ◽  
Vol 113 (3) ◽  
pp. 426-434 ◽  
Author(s):  
Bobbi Langkamp-Henken ◽  
Cassie C. Rowe ◽  
Amanda L. Ford ◽  
Mary C. Christman ◽  
Carmelo Nieves ◽  
...  
Keyword(s):  
Acute Stress ◽  
Bifidobacterium Longum ◽  
Daily Intake ◽  
Bifidobacterium Bifidum ◽  
Lactobacillus Helveticus ◽  
Lower Percentage ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Symptom Intensity

Acute psychological stress is positively associated with a cold/flu. The present randomised, double-blind, placebo-controlled study examined the effect of three potentially probiotic bacteria on the proportion of healthy days over a 6-week period in academically stressed undergraduate students (n 581) who received Lactobacillus helveticus R0052, Bifidobacterium longum ssp. infantis R0033, Bifidobacterium bifidum R0071 or placebo. On each day, participants recorded the intensity (scale: 0 = not experiencing to 3 = very intense) for nine cold/flu symptoms, and a sum of symptom intensity >6 was designated as a day of cold/flu. B. bifidum resulted in a greater proportion of healthy days than placebo (P≤ 0·05). The percentage of participants reporting ≥ 1 d of cold/flu during the 6-week intervention period was significantly lower with B. bifidum than with placebo (P< 0·05). There were no effects of B. infantis or L. helveticus compared with placebo on either outcome. A predictive model accounted for influential characteristics and their interactions on daily reporting of cold/flu episodes. The proportion of participants reporting a cold on any given day was lower at weeks 2 and 3 with B. bifidum and B. infantis than with placebo for the average level of stress and the most commonly reported number of hours of sleep. Daily intake of bifidobacteria provides benefit related to cold/flu outcomes during acute stress.

scholarly journals Suplementação com probióticos e depressão: estratégia terapêutica?

2019 ◽  
Vol 28 (1) ◽  
pp. 31
Author(s):  
Ana Letícia Ferreira de Moraes ◽  
Rosana Gomes Arruda Leite Bueno ◽  
Marta Fuentes-Rojas ◽  
Adriane Elisabete Costa Antunes
Keyword(s):  
Lactobacillus Acidophilus ◽  
Lactobacillus Casei ◽  
Bifidobacterium Longum ◽  
Bifidobacterium Bifidum ◽  
Lactobacillus Helveticus ◽  
Bifidobacterium Lactis

Evidências crescentes de que a microbiota intestinal pode influenciar no funcionamento do sistema nervoso central levaram à hipótese de que a suplementação com microrganismos chave pode ter um efeito positivo no tratamento da depressão. O objetivo desta revisão foi compilar dados da literatura científica sobre o impacto do uso de probióticos como estratégia terapêutica nos desfechos depressão e sintomas depressivos em humanos. As evidências compiladas nesta revisão indicam que a suplementação com probióticos apresenta potencial promissor como terapia adjuvante no tratamento dos sintomas associados ao transtorno de Depressão Maior e, principalmente, como ação preventiva de quadros depressivos em indivíduos saudáveis ou com depressão leve. O estado da arte aponta para o potencial efeito psicobiótico de determinadas culturas, tais como as espécies Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus helveticus, Bifidobacterium lactis, Bifidobacterium longum e Bifidobacterium bifidum recomendando-se para os próximos estudos a ênfase nas cepas específicas, dosagem e tempo de consumo para obtenção dos efeitos sobre o eixo intestino-cérebro.

Bifidobacterium bifidum R0071 decreases stress-associated diarrhoea-related symptoms and self-reported stress: a secondary analysis of a randomised trial

2016 ◽  
Vol 7 (3) ◽  
pp. 327-336 ◽  
Author(s):  
T. Culpepper ◽  
M.C. Christman ◽  
C. Nieves ◽  
G.J. Specht ◽  
C.C. Rowe ◽  
...  
Keyword(s):  
Undergraduate Students ◽  
Rating Scale ◽  
Bifidobacterium Longum ◽  
Randomised Trial ◽  
Secondary Analysis ◽  
Antibiotic Use ◽  
Bifidobacterium Bifidum ◽  
Lactobacillus Helveticus ◽  
Controlled Study ◽  
Double Blind

Psychological stress is associated with gastrointestinal (GI) distress. This secondary analysis from a randomised, double-blind, placebo-controlled study examined whether three different probiotics could normalise self-reported stress-associated GI discomfort and reduce overall self-reported stress. Undergraduate students (n=581) received Lactobacillus helveticus R0052, Bifidobacterium longum ssp. infantis R0033, Bifidobacterium bifidum R0071, or placebo. Participants self-reported 2 outcomes for a 6-week period, which included final academic exams: daily level of stress (0=no stress to 10=extremely stressed) and weekly three diarrhoea-related symptoms (DS, 1=no discomfort to 7=severe discomfort) using the GI Symptom Rating Scale. Self-reported stress was positively related to DS (P=0.0068). Mean DS scores were lower with B. bifidum versus placebo at week 2 at the average level of stress and the average body mass index (BMI). DS scores were lower with B. bifidum at week 5 versus week 0 and 1 and with B. infantis R0033 at week 6 versus week 0. DS scores were higher when antibiotics were used in the prior week with placebo (P=0.0092). DS were not different with or without antibiotic use with the probiotics. Only B. bifidum had an effect on self-reported stress scores (P=0.0086). The self-reported stress score was also dependent on hours of sleep per day where it decreased by 0.13 for each additional hour of sleep. During a stressful period, B. bifidum R0071 decreases DS and self-reported stress scores. This trial was registered at clinicaltrials.gov as NCT01709825.

Sign in / Sign up

Export Citation Format

Share Document